basis.
-- Non-GAAP Net Income and Earnings Per Share
The use of these non-GAAP measures allows management to monitor the
level of net income and earnings per share excluding both the costs of
our business transformation, in-process research and development costs,
as well as any related tax effects, and the favorable resolution of an
audit of prior year tax returns. We establish our budgets, forecasts,
and performance targets on this basis. Reconciliation of Non-GAAP Measures for the Fourth Quarter FY08 and FY07
03/29/08 03/31/07
Non-GAAP S,G&A
GAAP S,G&A $44,042 $31,815
Restructuring Costs (2,384) (586)
Non-GAAP S,G&A $41,658 $31,229
Non-GAAP Operating expenses
GAAP Operating Expenses $49,832 $32,655
Restructuring Costs (2,384) (586)
Baxter PI Settlement 5,700
Non-GAAP Operating Expenses $47,448 $37,769
Non-GAAP Operating income
GAAP Operating Income $20,309 $25,691
Restructuring Costs 2,384 586
Baxter PI Settlement (5,700)
Non-GAAP Operating income $22,693 $20,577
Non-GAAP Income before taxes
GAAP Income before taxes $21,382 $28,415
Restructuring Costs 2,384 586
Baxter PI Settlement (5,700)
Non-GAAP Income before taxes $23
'/>"/>
| SOURCE Haemonetics Corporation Copyright©2008 PR Newswire. All rights reserved |